Loading clinical trials...
Loading clinical trials...
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Conditions
Interventions
Savolitinib
Sunitinib
Locations
59
United States
Research Site
La Jolla, California, United States
Research Site
Atlanta, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Iowa City, Iowa, United States
Research Site
Boston, Massachusetts, United States
Research Site
Kansas City, Missouri, United States
Start Date
July 25, 2017
Primary Completion Date
August 18, 2019
Completion Date
December 31, 2026
Last Updated
April 14, 2026
NCT07175441
NCT07463573
NCT06563479
NCT06855771
NCT06340711
NCT06157151
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions